Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 1 of 9
Paradigm Biopharmaceuticals appoints Paul Rennie as MD after CEO Marco Polizzi steps down
The company's founder and non-executive chairman Paul Rennie will take the reins as MD during the transition period and thereafter.
Paradigm Biopharmaceuticals’ clinical trial data on injectable PPS in metabolic disease to feature at WORLDSymposium 2023
“The data from this trial will be invaluable for further development for potential registration of iPPS for this indication,” said CEO Marco Polizzi.
Paradigm Biopharmaceuticals begins dosing first UK subject in pivotal iPPS/Zilosul® trial
The purpose of this phase three study is to establish the efficacy of subcutaneous injections of PPS (iPPS) participants with knee osteoarthritis pain.
Paradigm Biopharmaceuticals achieves high levels of pain reduction in PARA_OA_008 osteoarthritis trial; shares jump
“These are meaningful signals that we will evaluate together with clinical and imaging outcomes in order to demonstrate disease-modifying effects and to pursue regulatory authority guidance on a disease-modifying pathway," said chief medica
Paradigm Biopharmaceuticals passes milestone on completing safety review for MPS VI phase 2 clinical trial
This milestone now allows the inclusion of subjects aged 5 to 9 years to assess the safety and tolerability of PPS amongst this paediatric population.
Paradigm Biopharmaceuticals closes A$20.3 million entitlement offer, raising A$66 million in total
The fully underwritten placement and offer are set to give PAR a proforma cash position of A$108.5 million to fund it into 2024.
Paradigm Biopharmaceuticals appoints interim company secretary
Abby Macnish has been appointed to the role in an interim capacity following the passing of long-term company secretary Kevin Hollingsworth.
Paradigm Biopharmaceuticals to raise $66 million to fund it through to CY24
The placement received strong participation from domestic and offshore institutional investors and once completed, a global long only institutional investor will become a substantial shareholder.
Paradigm Biopharmaceuticals invited to present on pentosan polysulfate sodium at lysosomal diseases conference
“We are very excited by the global recognition of Paradigm’s clinical development in this rare disease and the opportunity to present the exciting work we are undertaking at the International Conference on Lysosomal Diseases early next year